文献速递消化系统肿瘤

转移性结直肠癌中的NeoRAS野生型:迷思还是真相?——病例系列与文献综述

NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature.
PubMed 文献 · Eur J Cancer · 2021-06-18

本文报道3例转移性结直肠癌患者在接受标准治疗后出现RAS突变型转为RAS野生型(NeoRAS野生型)现象,其中2例后续使用抗EGFR抗体,1例获长期缓解。结合文献综述提示NeoRAS野生型在临床实践中确实存在,对RAS突变型mCRC长程非典型病程者应讨论治疗中重新检测RAS状态。

要点

  • RAS突变型mCRC治疗后转为RAS野生型(NeoRAS野生型)现象在临床实践中存在。
  • 3例NeoRAS野生型患者中2例后续使用抗EGFR抗体,1例获长期缓解。
  • RAS突变型mCRC长程非典型病程者应讨论治疗中重新检测RAS状态。

核心结论

  • NeoRAS野生型现象在临床实践中确实发生,RAS突变型mCRC患者治疗中重新检测RAS状态值得讨论。
  • 对RAS突变型mCRC长程非典型临床病程者,重新检测RAS状态有助于优化治疗策略并评估抗EGFR抗体使用。

研究设计与样本

  • 病例系列报道3例NeoRAS野生型mCRC患者,均接受RAS突变型mCRC的标准治疗方案。
  • 结合文献综述讨论NeoRAS野生型现象及化疗对mCRC患者RAS状态的影响。

主要发现

  • 3例患者中2例在疾病进展后使用抗EGFR抗体,其中1例获长期缓解。
  • RAS野生型转为RAS突变型是抗EGFR抗体治疗已知的获得性耐药机制,而RAS突变型转为RAS野生型(NeoRAS野生型)远较少见。

关键数值与推荐

  • mCRC一线治疗前KRAS和NRAS基因检测(RAS)为标准诊疗,RAS突变是抗EGFR抗体疗效的负性预测因子。
  • 西妥昔单抗和帕尼单抗仅限用于RAS野生型mCRC。

临床怎么用

  • RAS突变型mCRC患者若出现非典型长程临床病程,可讨论治疗中重新检测RAS状态。
  • NeoRAS野生型患者后续使用抗EGFR抗体的策略需进一步评估。

局限性

  • 本文为病例系列(3例)结合文献综述,样本量小,证据级别有限。
  • 化疗对mCRC患者RAS状态的影响尚未完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Upfront KRAS and NRAS gene testing ('RAS') is the standard of care for metastatic colorectal cancer (mCRC), to guide first-line treatment. The presence of RAS mutation (MT) is a negative predictor for the efficacy of anti-EGFR antibodies and the use of cetuximab and panitumumab is restricted to RAS wild-type (WT) mCRC. Conversion from RAS WT to RAS MT mCRC after treatment with anti-EGFR antibodies is a known and well-described acquired resistance mechanism. The by far less frequent 'NeoRAS wild-type' phenomenon (reversion from RAS MT to RAS WT) has recently drawn attention. The proposed effect of chemotherapy on RAS status in mCRC patients is not fully understood. Because of the intriguing biological consequence of a RAS MT to RAS WT reversion, subsequent treatment of NeoRAS WT patients with anti-EGFR antibodies is increasingly being discussed. Here, we report three clinical cases of NeoRAS WT mCRC patients, which received standard-of-care regimens for RAS MT mCRC. Anti-EGFR antibodies were used in two out of three patients after progression of the disease. One of the patients had a long-term response. In line with our observations, NeoRAS WT phenomenon occurs in clinical practice. Retesting of RAS status during treatment should be discussed in patients with unusual long-term clinical courses of RAS MT mCRC to optimise treatment strategy and to evaluate the use of anti-EGFR antibodies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Osumi H, Vecchione L, Keilholz U, et al. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature. Eur J Cancer. 2021. PMID: 34153718. doi:10.1016/j.ejca.2021.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。